Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Sakai
Clinical trial register · Japan

Clinical Trials in Sakai, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2493 matching records held by the registry are in this view. Synced 22 Oct 2026, 03:19 UTC
2493
Studies in scope
all four open statuses
1263
Recruiting now
open to new participants
349
Lead sponsors
across recruiting studies
Top sites
Fukuoka 551 Nagoya 517 Sapporo 398 Tokyo 369 Osaka 348
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Merck Sharp & Dohme LLC12 Pfizer11 Chugai Pharmaceutical4 Novartis Pharmaceuticals4 Sanofi4
Site location
Fukuoka551 Nagoya517 Sapporo398 Tokyo369 Osaka348
All 926 locations
Target enrolment
to

Trials with a site in Sakai

60 of 2493 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Japan
Start
Recruiting
Pfizer
Phase 3
1,375
Nagoya, Kagoshima, Yokohama, Sakai, Saitama, Chuo-ku, Tachikawa, Toshima-ku
2026-08-24
Recruiting
Novartis Pharmaceuticals
Phase 3
180
Yokohama, Sakai, Tachikawa
2026-08-24
Recruiting
Pfizer
Phase 3
375
Matsudo, Teine-ku, Nagaoka, Sakai, Shinagawa, Osaka
2026-08-17
Recruiting
AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer
NCT07617337ALK Positive Non-small Cell Lung Cancer
DrugLorlatinib
Chugai Pharmaceutical
Phase 1
102
Nagoya, Kashiwa, Sakai, Nagaizumi-cho, Chuo-ku, Koto-Ku
2026-07-24
Recruiting
Ono Pharmaceutical Co., Ltd.
Phase 1
80
Kashiwa, Maebashi, Niigata, Hirakata, Osaka, Sakai, Hidaka, Sunto-gun
2026-06-19
Recruiting
Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)
NCT07637734Common Warts, Common Warts (Verruca Vulgaris), Human Papilloma Virus (HPV), Warts
Verrica Pharmaceuticals Inc.
Phase 3
300
Sapporo, Kamimashiki-gun, Kumamoto, Sakai, Saitama, Tokyo
2026-06-15
Recruiting
Bristol-Myers Squibb
Phase 3
850
Nagoya, Kobe, Nishinomiya, Sagamihara, Yokohama, Sendai, Hirakata, Sakai
2026-03-16
Recruiting
Astellas Pharma Global Development, Inc.
Phase 3
614
Kashiwa, Matsuyama, Fukuoka, Kashihara-shi, Sakai, Suita, Bunkyo-ku, Koto
2026-02-17
Recruiting
Pfizer
Phase 2/3
1,156
Nagoya, Fukuoka, Iizuka-shi, Kure, Ginowan, Sakai, Fujieda, Hachiōji
2026-02-11
Recruiting
Genmab
Phase 2
240
Sagamihara, Yokohama, Kyoto, Nagoya, Saitama, Sakai, Chūō, Tokyo
2026-01-30
Active, closed
Janssen Research & Development, LLC
Phase 2
189
Matsudo, Nishiku, Sakai, tabashi City, Tachikawa, Yokohama
2026-01-20
Active, closed
UCB Biopharma SRL
Phase 2
165
Habikino, Nagoya, Sakai, Sapporo, Tachikawa-shi, Yokohama
2025-12-29
Active, closed
A Clinical Evaluation of AMJ-401
NCT07373353Ischemic Heart Disease (IHD)
Abbott Medical Devices
Not applicable
50
Toyoake, Tokyo, Kitakyushu, Shiwa-gun, Kamakura, Kawasaki, Miyazaki, Sakai
2025-12-17
Recruiting
Bristol-Myers Squibb
Phase 3
650
Hadano, Kawasaki, Sakai, Kanzaki-Gun Yoshinogari-Cho, Karatsu-shi, Bunkyo-ku, Fukuoka, Okayama
2025-12-02
Recruiting
Pfizer
Phase 3
450
Yokohama, Sakai, Setagaya-ku, Fukuoka
2025-12-02
Recruiting
Pfizer
Phase 1/2
138
Nagoya, Kashiwa, Sakai, Chuo-ku, Fukuoka
2025-12-01
Active, closed
Kymera Therapeutics, Inc.
Phase 2
200
Ichikawa, Kagoshima, Kanagawa, Nagoya, Osaka, Sakai, Sapporo
2025-11-24
Recruiting
Pfizer
Phase 2
165
Takasaki, Kawasaki-shi, Yokohama, Sakai, Chuo-ku
2025-11-20
Recruiting
Pfizer
Phase 2
200
Takasaki, Yokohama, Sakai, Tachikawa, Miyazaki
2025-10-30
Recruiting
Chugai Pharmaceutical
Phase 1
122
Kashiwa, Tōon, Sakai, Niigata
2025-10-08
Recruiting
Pfizer
Phase 3
150
Yokohama, Sakai, Setagaya-ku, Fukuoka
2025-07-24
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,000
Nagoya, Matsuyama, Sapporo, Tsu, Hirakata, Sakai, Hidaka, Sunto-gun
2025-07-21
Recruiting
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
NCT06765109Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive
DrugsNeladalkib·Alectinib
Nuvalent Inc.
Phase 3
450
Fukuoka, Chikusa, Nagaizumi-chō, Okayama, Osaka, Sakai, Tokyo, Wakayama
2025-07-17
Recruiting
Merck Sharp & Dohme LLC
Phase 3
477
Nagoya, Kashiwa, Sapporo, Kita-gun, Yokohama, Sendai, Sakai, Hidaka
2025-07-16
Recruiting
Bristol-Myers Squibb
Phase 3
426
Hadano, Kawasaki, Sakai, Kanzaki-Gun Yoshinogari-Cho, Karatsu-shi, Bunkyo-ku, Fukuoka, Okayama
2025-07-10
Recruiting
Pfizer
Phase 2
252
Aki-gun Fuchu-cho, Kobe, Kawachi-Nagano, Sakai, Fujieda, Hamamatsu, Chuo-ku, Hachiōji
2025-05-20
Recruiting
Bayer
Phase 1/2
450
Nagoya, Kashiwa, Sakai, Sunto, Chuo-ku, Koto-ku
2025-03-21
Recruiting
Bayer
Phase 2
111
Nagoya, Kashiwa, Sapporo, Sakai, Chuo-ku, Koto-ku
2025-02-13
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,046
Nagoya, Kashiwa, Matsuyama, Kobe, Kanazawa, Isehara, Sendai, Sakai
2025-01-27
Recruiting
Janssen Research & Development, LLC
Phase 3
700
Chiba, Chūōku, Kashiwa, Nagoya, Osaka, Sakai, Shizuoka, Suita
2024-12-12
By invitation
Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)
NCT06723106Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS), Dermatomyositis (DM)
DrugRAY121
Chugai Pharmaceutical
Phase 1
144
Sapporo, Himeji, Isehara, Sendai, Kawachi-Nagano, Sakai, Suita, Hamamatsu
2024-12-09
Active, closed
Merck Sharp & Dohme LLC
Phase 3
67
Toyoake, Tōon, Kitakyushu, Takarazuka, Yokohama, Nankoku, Natori-shi, Sakai
2024-11-21
Recruiting
Osaka Cardiometabolic Epidemiological Study: Ohtori Study Part 2
NCT06694012Type 2 Diabetes Mellitus (T2DM), Type 2 Diabetes, Diabetes Mellitus, Hypertension
Osaka Metropolitan University
Observational
2,000
Sakai
2024-11-01
Recruiting
Merck Sharp & Dohme LLC
Phase 3
680
Kashiwa, Kitakyushu, Kawasaki, Yokohama, Hirakata, Sakai, Sunto-gun, Shimotsuga-gun
2024-10-21
Recruiting
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
NCT06371417Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS), Dermatomyositis (DM)
DrugRAY121
Chugai Pharmaceutical
Phase 1
144
Sapporo, Himeji, Isehara, Sendai, Sakai, Suita, Hamamatsu, Bunkyō-Ku
2024-08-19
Recruiting
NovoCure GmbH
Phase 3
734
Sakai, Hidaka, Bunkyo, Chuo-ku
2024-07-31
Recruiting
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
NCT06427941Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma, Alpha-fetoprotein (AFP)-Producing Gastric Cancer, Extragonadal Yolk Sac Tumors
DrugsTislelizumab·Bevacizumab
BeOne Medicines
Phase 1/2
630
Sakai, Bunkyoku, Kotoku
2024-07-23
Recruiting
AstraZeneca
Phase 3
582
Chūōku, Fukuoka, Kashiwa, Kōtoku, Niigata, Osaka, Sakai, Sapporo
2024-04-29
Recruiting
Merck Sharp & Dohme LLC
Phase 3
780
Kashiwa, Matsuyama, Kitakyushu, Kobe, Kawasaki, Yokohama, Hirakata, Sakai
2024-04-03
Active, closed
Sanofi
Phase 3
464
Yokohama, Habikino, Sakai, Mibu, Minato, Tachikawa, Hiroshima, Sapporo
2024-02-29
Active, closed
Pfizer
Phase 3
394
Nagoya, Sendai, Sakai, Bunkyo-ku, Shinjuku-ku, Kofu
2024-01-19
Active, closed
Merck Sharp & Dohme LLC
Phase 2
147
Sakai, Tokyo
2023-12-26
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,200
Nagoya, Maebashi, Sapporo, Kobe, Sendai, Sakai, Izumo, Koto
2023-12-13
Recruiting
Merck Sharp & Dohme LLC
Phase 3
735
Nankoku, Sakai, Koto, Hiroshima, Nagasaki, Osaka, Yamagata
2023-08-08
Active, closed
Novartis Pharmaceuticals
Phase 3
100
Kitakyushu, Kamimashi-gun, Sakai, Izumo, Itabashi-ku
2023-07-11
Active, closed
Sanofi
Phase 2
999
Obihiro, Yokohama, Sakai, Mibu, Tachikawa
2023-04-03
Active, closed
Novartis Pharmaceuticals
Phase 3
696
Nagoya, Urayasu, Obihiro, Yokohama, Kamimashi-gun, Izumiōtsu, Neyagawa, Sakai
2022-12-09
Active, closed
Sanofi
Phase 2/3
1,856
Chitose, Obihiro, Sapporo, Sagamihara, Yokohama, Habikino, Sakai, Iruma
2022-08-22
Active, closed
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
NCT05458297Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
DrugsZilovertamab vedotin·Nemtabrutinib
Merck Sharp & Dohme LLC
Phase 2
189
Nagoya, Sapporo, Isehara, Sendai, Sakai, Chuo-ku, Koto, Fukuoka
2022-07-21
Recruiting
Astellas Pharma Global Development, Inc.
Phase 1
398
Nagoya, Kashiwa, Yokohama, Sakai, Suita, Chuo-ku, Koto-ku
2022-06-07
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,800
Toyoake, Kashiwa, Sakura, Tōon, Sapporo, Yokohama, Kashihara, Sakai
2022-03-15
Recruiting
Sanofi
Phase 3
284
Matsudo, Urayasu, Sapporo, Yokohama, Habikino, Sakai, Izumo, Tachikawa
2022-02-15
Active, closed
AstraZeneca
Phase 3
454
Chūōku, Fukuoka, Kashiwa, Matsuyama, Niigata, Okayama, Osaka, Sakai
2021-10-28
Recruiting
Bayer
Phase 1/2
430
Nagoya, Kashiwa, Matsuyama, Sapporo, Yokohama, Sakai, Sunto, Chuo-ku
2021-10-25
Active, closed
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
NCT04971226Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
DrugsBosutinib·Asciminib·ABL001·Nilotinib
Novartis Pharmaceuticals
Phase 3
405
Nagoya, Toyoake, Sapporo, Kobe, Kurashiki, Sakai, Suita, Shimotsuke
2021-10-06
Active, closed
Savara Inc.
Phase 3
164
Chiba, Sapporo, Yokohama, Kumamoto, Sendai, Sakai, Saitama, Mitaka
2021-05-19
Active, closed
Merck Sharp & Dohme LLC
Phase 3
747
Toyoake, Kashiwa, Sakura, Sapporo, Kobe, Yokohama, Kashihara, Sakai
2021-02-25
Recruiting
Taiho Pharmaceutical Co., Ltd.
Phase 1
59
Bunkyō City, Fukushima, Iruma, Kyoto, Nagasaki, Osaka, Sakai, Shinagawa-Ku
2020-10-30
Active, closed
Pfizer
Phase 3
1,068
Matsuyama, Tōon, Fukuoka, Ōta, Sapporo, Yokohama, Osaka, Sakai
2019-12-30
Recruiting
Product Surveillance Registry
NCT01524276Cardiac Rhythm Disorders, Urological Disorders, Neurological Disorders, Cardiovascular Disorders
Medtronic
Observational
100,000
Sakai, Ageo, Hidaka, Koshigaya, Tokyo, Bunkyō-Ku, Minato-Ku, Yonago
2012-01
Rows per page Showing 1–60 of 60
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 October 2026. https://priyalifescience.com/clinical-trials-japan/city/sakai

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,493 studies in total at the last sync on 22 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 60 of those studies with a site in Sakai.

How many clinical trials are recruiting in Sakai?

40 of the 60 studies on this page are recruiting new participants as of the 22 Oct 2026, 03:19 UTC sync. A further 0 have not yet opened recruitment, 19 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Sakai), 60 studies
PhaseStudiesRecruitingShare
Phase 3332255%
Phase 211518.3%
Phase 17611.7%
Phase 1/2446.7%
Observational223.3%
Phase 2/3213.3%
Not applicable101.7%

Most active sponsors

Lead sponsors with the most studies (Sakai)
Lead sponsorStudiesRecruiting
Merck Sharp & Dohme LLC127
Pfizer119
Chugai Pharmaceutical43
Novartis Pharmaceuticals41
Sanofi41
Bayer33
Bristol-Myers Squibb33
Astellas Pharma Global Development, Inc.22
AstraZeneca21
Janssen Research & Development, LLC21
→

Other trial registries in Japan

This register lists Japan studies from ClinicalTrials.gov. Many studies in Japan are registered only in a national registry. We do not copy those records; search them directly:

  • jRCT (Japan Registry of Clinical Trials) — run by the Ministry of Health, Labour and Welfare; trials under Japan's Clinical Trials Act and other clinical research
  • UMIN-CTR — run by the University of Tokyo Hospital's UMIN Center; many academic and investigator-led studies
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.